Dr Meral Kayikcioglu

Collaborating with great minds today at the EAS LATAM Meeting 🇪🇺🌎 We're working on meaningful steps to improve cardiovascular atherosclerotic disease across Latin America. Proud to be part of the conversations shaping real change. @society_eas #LATAMScience

Published in Atherosclerosis; Our joint editorial by @society_eas EC & the @ATHjournal editorial board — reaffirming the critical need for #sex & #gender integration in ASCVD research & clinical care. 🧬 Sex hormones, chromosomes & social roles all matter. ⚠️ Without this lens,…

Prévention Primaire CV made in TAIWAN medvasc.info/archives-blog/… @LaurenMerzMD @NMerke @MeralKayikcoglu @vanessabmalaqui @Williambaraka11 @alainpaulweber @kerstindewit @LionelREICHARDT @CorinneFrereMD @iatros256395 @CNCHcollege @CordierCaroline @FCouturaud @FR_Conversation

SEX AND GENDER IN ATHEROSCLEROSIS ⚧️It's essential rol in CV researc ⚧️A statement from the Editorial Board of Atherosclerosis and Executive Committee of the European Atherosclerosis Society ⚧️Highlights on . Sex differences . Transgender individuals . Gender differences #CardioX

Canicule et Santé medvasc.info/archives-blog/… @GendronNico @BozonGuillaume @LauraRu1578 @davidlisnard @GoudotG @Segodebruyne @MeralKayikcoglu @MohammedAlo @DrGomi @flobretelle @NChakfe @MedvascC @ClubVasculaire @MedVasc_HEGP @BonnotOlivier @jbdefrem @JBezivin @NoTruffe

This autumn, we’re launching a new series of Advanced Courses on Non-classical risk factors for cardiovascular disease! If you're a clinician or healthcare practitioner and want to deepen your understanding of chronic inflammation, metabolic disturbances, gut microbiota,…

ESC late breakers you might be interested in Mon- presented by Jessica Schubert & Steve Nicholls. Sat 5.40 Science Box 5 - independent & joint effects of obesity & metabolic abnormalities on ASCVD, HF, MASLD and ESRD in males & females 1.9 m PY FU

We are heartbroken over the fire in Chios — and now Foça is burning too. So many places across the Aegean are in flames. 💔🌿 #AegeanFires #Foça #Chios #Greece #Turkiye

🌍 Happy to share the 2nd edition of the EAS-LIPRA Newsletter, featuring highlights from our National Societies and also a message from me as Chair of @society_eas National Societies: "The EAS is now a truly global society, with 60+ member countries. It's time to unite across…

New JACC/ACC performance measures tighten LDL targets to <55 mg/dL for high-risk ASCVD—pushing earlier and more aggressive lipid management. Will this shift change clinician behavior in real-world prevention? Can we overcome existing inertia? jacc.org/doi/10.1016/j.…

📢 New publication from the EAS Lipid Registry of Africa (LIPRA)! 🌍🫀 Premature coronary artery disease, acute coronary syndrome, and lipoprotein(a) should be prioritised in African lipidology and preventive cardiology, according to our expert panel. Discover the results of a…

Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a). Mechanism driving ASCVD likely differ for LDL, remnants and Lp(a). academic.oup.com/eurheartj/adva… Anders B Wulff & BG Nordestgaard in Eur Heart J

Our latest work is out in @ATH_Plus As the EAS-LIPRA team, we identified Africa’s top priorities in lipidology & preventive cardiology using the Delphi method. Highlights: ✅ Lp(a) prevalence ✅ Premature CAD ✅ ASCVD burden ✅ Risk scores for African populations 📖…

A sad day for #echofirst. Our world has lost a giant with the passing of Roberto Lang, MD @robertomlang. Scholar, teacher, echo pioneer, and leader (President @ASE360 2009-2010) -- but most of all a kind and gentle person. Condolences to his family. May his memory be a blessing.

Summer is calling… 🌊☀️ Wishing all my friends, near and far — and especially my EAS family — a peaceful, joyful, & sunny summer. May we find moments of rest, beauty, and inspiration by the sea or wherever the season takes us. #SummerIsComing #AegeanVibes #PeacefulSummer…

🚨New publication alert in @EJHFEiC Collaborative effort across cardiology and hepatology Key Findings 1️⃣18% of patients with biopsy-proven MASLD developed HF➡️ HFpEF 2️⃣50% met criteria for suspicion of HF 3️⃣Risk was highest among older adults, women, and those with diabetes

Professor Mansoor Husain, Co-Chair of the EAS Consensus Panel, shares his perspective on the newly published EAS Consensus Statement. The proposed clinical staging system marks an important shift in how we identify and manage metabolic disorders—moving from a reactive to a…

JACC STATE-OF-THE-ART REVIEW: do you have problems understanding all the new drugs to lower triglycerides and remnant cholesterol: lipid and side effects, target populations, approved or not by FDA+EMA? Ask Tybjærg Nordestgaard et al explain the details authors.elsevier.com/a/1l4pB2d9GI27…